Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

What is TB-500 Peptide? A Researcher’s Breakdown

When you're deep in the world of advanced biological research, certain compounds generate a persistent, unavoidable buzz. You hear them discussed in labs, cited in preclinical studies, and debated in scientific forums. For our team, one of the most consistentl

By Recovery & Performance Peptides Editorial Team

When you're deep in the world of advanced biological research, certain compounds generate a persistent, unavoidable buzz. You hear them discussed in labs, cited in preclinical studies, and debated in scientific forums. For our team, one of the most consistently fascinating molecules in this category is TB-500. It's a peptide that sits right at the heart of one of biology's most fundamental processes: healing and regeneration.

But what is TB-500 peptide, really? It's a question we get all the time. The short answer is that it's a synthetic version of a naturally occurring protein fragment. The long answer, however, is far more compelling. It's a story that involves cellular mechanics, intricate protein interactions, and the profound potential to understand and influence the body's own repair systems. At Real Peptides, we believe that empowering researchers starts with providing not just high-purity compounds, but also the deep, authoritative knowledge needed to use them effectively. So, let's unpack the science behind this remarkable peptide.

The Origin Story: From Thymus Gland to Synthetic Peptide

To really grasp what TB-500 is, we have to go back to its source. It all starts inside the body, specifically with a protein called Thymosin Beta-4 (Tβ4). This protein is not some rare, exotic molecule; it's found in virtually all human and animal cells, though it's found in particularly high concentrations in certain tissues and platelets. Tβ4 is a powerhouse of a protein, involved in a sprawling list of biological functions, from immune response to tissue remodeling.

It’s a big molecule. Tβ4 is composed of 43 amino acids, and scientists discovered that not all of them were required to produce its most potent regenerative effects. They pinpointed a specific, shorter section of the protein that seemed to be the primary driver of its most sought-after function: the promotion of cell migration and healing. This active region is what we now know as TB-500. It's the synthetic, lab-created counterpart to that crucial fragment of the natural Tβ4 protein. This distinction is critical. We're not talking about harvesting a protein from a natural source; we're talking about precise, repeatable synthesis that isolates the most effective part of the molecule for research purposes.

This is why precision matters so much in our industry. When we synthesize a product like our TB 500 Thymosin Beta 4, we are recreating that exact, powerful fragment. There's no room for error. The sequence has to be impeccable for the research to be valid.

How Does TB-500 Actually Work? The Science of Actin

Now, this is where it gets interesting. The primary mechanism of action for TB-500 is elegant and profoundly important. It all revolves around a protein called actin.

If you think of a cell as a bustling city, actin is the scaffolding, the transportation network, and the construction crews all rolled into one. It's a protein that can assemble into long chains, or filaments, creating the cell's internal skeleton (the cytoskeleton). This skeleton isn't static; it's constantly being built up and broken down, allowing the cell to change shape, move, and divide. This process is called actin polymerization, and it's fundamental to life.

TB-500's role is that of a master regulator of actin. It's what's known as an actin-sequestering protein. In simple terms, it binds to individual actin molecules (monomers), preventing them from spontaneously forming filaments. Think of it as holding building blocks in reserve. When a cell needs to move—perhaps to migrate to the site of an injury—it needs to rapidly build new actin filaments in the direction of travel. TB-500 facilitates this by releasing its stored actin monomers precisely where they are needed most. This localized release allows for the rapid construction that powers cell motility.

Our team has found that this is the concept researchers often miss. TB-500 doesn't just randomly stimulate healing. No, it enables one of the core processes required for it. By upregulating actin, it gives cells the raw materials and the green light to:

Migrate: Endothelial cells (which line blood vessels) and keratinocytes (skin cells) can travel to a wound site much more efficiently.

Differentiate: Stem cells can better differentiate into the specific cell types needed for repair.

Survive: It promotes cell survival in environments with low oxygen, such as the core of a wound.

This isn't a blunt instrument. It’s a nuanced, sophisticated mechanism that works with the body's existing systems, optimizing a process that is already in place. The systemic nature of TB-500 means its influence isn't confined to a single injection site; its effects on actin regulation can be observed throughout the body, which is a key differentiator from other regenerative peptides.

TB-500 vs. BPC-157: A Common Point of Confusion

If you're exploring regenerative peptides, you've undoubtedly come across BPC 157 Peptide. Researchers frequently ask us to clarify the difference between these two, as they are often studied for similar purposes. While both are stars in the field of tissue repair research, their mechanisms and ideal study parameters are quite different. Honestly, thinking of them as interchangeable is a significant mistake.

BPC-157, derived from a body protection compound found in gastric juice, primarily exerts its effects by promoting angiogenesis—the formation of new blood vessels—and by interacting with the nitric oxide pathway and various growth factors. It's renowned for its ability to accelerate the healing of ligaments, tendons, and the gut lining, often with a more pronounced localized effect. The Wolverine Peptide Stack on our site, which combines both, is popular specifically because researchers want to study these complementary, not identical, pathways.

TB-500 works systemically through the actin upregulation we just discussed. It's less about creating new blood supply (though it contributes to that) and more about improving the mobility and function of the cells that perform the repairs. Our experience shows that this makes it an exceptional candidate for studies involving widespread inflammation, soft tissue damage, and situations where overall systemic recovery needs to be investigated.

Here’s a breakdown our team put together to clarify the key distinctions:

Primary Mechanism

Actin Upregulation & Cell Migration

Angiogenesis & Growth Factor Modulation

Scope of Action

Systemic

Primarily Localized (but has systemic effects)

Natural Origin

Fragment of protein found in all human/mammal cells

Synthetic peptide derived from a gastric juice protein

Key Research Area

Soft tissue repair, inflammation, cell mobility

Tendon/ligament healing, gut health, tissue regeneration

Our Observation

Excellent for widespread, systemic recovery studies

Unparalleled for targeted, site-specific injury models

They aren't competitors; they're two different tools for investigating two different, albeit related, aspects of biological repair.

Key Areas of Preclinical Research for TB-500

The unique, systemic mechanism of TB-500 has made it a subject of intense interest across a surprisingly broad spectrum of preclinical research. Its potential isn't limited to just one type of tissue or one kind of injury. The applications are sprawling.

One of the most established areas is, unsurprisingly, wound healing. Studies in animal models have shown that administration of Tβ4 can dramatically accelerate the closure of dermal wounds, reduce scar formation, and improve the overall quality of the repaired tissue. This makes sense—by improving the migration of skin cells and the cells that form blood vessels, you're fundamentally speeding up the entire reconstruction process.

But it goes deeper. There's a significant body of research into its cardioprotective effects. After an ischemic event like a heart attack, a great deal of damage is caused by the death of heart muscle cells (cardiomyocytes). Preclinical studies suggest that Tβ4 can help preserve these cells, promote the growth of new blood vessels in the damaged area, and reduce inflammation, ultimately leading to better functional recovery of the heart muscle. This is a formidable area of study, and we've seen a definite uptick in orders from cardiovascular research labs.

Another electrifying frontier is its role in neurological recovery. From traumatic brain injury (TBI) to stroke, the brain has a limited capacity for self-repair. Research indicates that TB-500 may promote neurogenesis (the creation of new neurons) and angiogenesis in the brain, helping to repair damaged neural circuits. It also appears to have a potent anti-inflammatory effect within the central nervous system, which is a critical factor in limiting secondary damage after an initial injury.

We also can't ignore its powerful anti-inflammatory properties. Inflammation is a double-edged sword; it's necessary to kickstart healing but can cause significant damage if it becomes chronic or excessive. TB-500 has been shown to modulate inflammatory pathways by down-regulating a number of pro-inflammatory cytokines. This helps to create a more favorable environment for tissue regeneration to occur, free from the destructive effects of runaway inflammation. This effect is not an afterthought; it's central to its regenerative capabilities.

Ensuring Quality and Purity in Your Research

Let's be honest. In the world of peptide research, your results, your data, and your conclusions are only as reliable as the compounds you start with. It's a critical, non-negotiable element of good science. A peptide that is under-dosed, contaminated with synthesis byproducts, or has an incorrect amino acid sequence won't just give you poor results—it will give you invalid results. It can derail a research project, wasting invaluable time and funding.

This is the problem our company was founded to solve. We can't stress this enough: sourcing matters. At Real Peptides, we're built on a foundation of unflinching commitment to purity and accuracy. Our process involves small-batch synthesis, which allows for much tighter quality control compared to mass production. Every single batch of our peptides, including our TB 500 Thymosin Beta 4, undergoes rigorous third-party testing to verify its identity, purity, and concentration. We make these Certificates of Analysis readily available because transparency is the bedrock of scientific trust.

When you're preparing a compound for a study, you also need the right supplies. The peptide itself is usually in a lyophilized (freeze-dried) powder state and must be reconstituted. This requires a sterile solvent, most commonly Bacteriostatic Water, to ensure the sample remains sterile and stable for the duration of the experiment. Cutting corners on any part of this process introduces variables that can compromise your entire data set. We believe researchers deserve better, which is why we provide a complete ecosystem of high-quality products to support their work from start to finish.

Navigating the Research Landscape

It’s crucial to understand the context in which TB-500 exists. This is a compound intended strictly for in-vitro and preclinical research purposes only. It has not been approved by the FDA or any other major regulatory body for human use or consumption. Any discussion of its effects is based on laboratory and animal studies.

Furthermore, because of its potent regenerative capabilities, Thymosin Beta-4 is listed on the World Anti-Doping Agency's (WADA) Prohibited List. This is an important piece of information that underscores its biological activity and confirms its status as a powerful research agent, not a supplement.

For researchers, proper handling is paramount. Once reconstituted, peptides like TB-500 are sensitive to temperature and light. They must be stored in a refrigerator to maintain their stability and efficacy. For long-term storage, freezing the lyophilized powder is the standard protocol. For a more visual guide on lab best practices and reconstitution techniques, our team has put together some helpful videos over on our YouTube channel that walk through these essential procedures.

This landscape demands responsibility and integrity, both from the researchers conducting the studies and from the suppliers providing the materials. Our mission is to operate as a trusted partner to the scientific community, ensuring every vial we ship meets the exacting standards required for groundbreaking work. You can see this commitment across our full peptide collection.

The journey of understanding a peptide like TB-500 is a perfect example of modern biomedical science. It begins with a naturally occurring protein, moves to the precise isolation of its active component, and culminates in rigorous laboratory investigation to unlock its full potential. It’s a molecule that bridges the gap between the body's innate wisdom and the power of scientific innovation. For any research team looking to explore the frontiers of healing and regeneration, TB-500 represents a profoundly exciting area of study. If you're ready to explore this fascinating area of biotechnology, you can Get Started Today by exploring our rigorously tested research compounds.

Frequently Asked Questions

Thymosin Beta-4 (Tβ4) is the full, naturally occurring 43-amino acid protein found in the body. TB-500 is the synthetic peptide that represents the most biologically active fragment of the Tβ4 protein, making it more targeted for research into healing and regeneration.

No, absolutely not. TB-500 is a peptide, which is a short chain of amino acids. Steroids are a class of organic compounds with a completely different chemical structure and biological mechanism of action, primarily interacting with androgen receptors.

Before reconstitution, the lyophilized (freeze-dried) powder should be stored in a freezer for long-term stability. After being reconstituted with bacteriostatic water, the solution must be kept refrigerated and protected from light to maintain its integrity.

Actin upregulation refers to the process where TB-500 binds to actin monomers, regulating their availability. This allows a cell to rapidly build and break down its internal scaffolding (cytoskeleton), which is essential for cell movement, division, and repair.

Purity is paramount because any contaminants or incorrect amino acid sequences can alter the biological activity of the peptide, leading to inaccurate or invalid research data. Our team at Real Peptides emphasizes third-party testing to guarantee that researchers are working with the exact molecule they intend to study.

Yes, many researchers study them in combination to investigate potentially synergistic effects. Because they work through different primary mechanisms (actin regulation for TB-500 and angiogenesis for BPC-157), studying them together can provide a more comprehensive picture of tissue repair.

A systemic effect means the peptide’s influence is not confined to the site of administration but is distributed throughout the body via the bloodstream. TB-500’s ability to regulate actin is a systemic process, affecting cells in various tissues and organs.

Yes, Thymosin Beta-4 and its derivatives like TB-500 are on the World Anti-Doping Agency (WADA) Prohibited List. This underscores its potent biological activity and confirms its status as a compound for research, not for use in competitive sports.

Reconstitution is the process of adding a sterile solvent, like bacteriostatic water, to a lyophilized (freeze-dried) peptide powder to turn it into a liquid solution suitable for use in experiments. This must be done carefully to ensure sterility and accurate concentration.

Absolutely. We provide a Certificate of Analysis (CoA) from a third-party lab with every batch. This document verifies the peptide’s purity, identity, and concentration, ensuring our research clients have complete confidence in their materials.

TB-500 is studied in a wide range of preclinical models. This includes in-vitro cell cultures to observe cell migration and in-vivo animal models (typically rodents) to study its effects on wound healing, cardiovascular repair, and neurological recovery.

No, like most peptides, TB-500 is not orally bioavailable. The digestive system would break down the peptide bonds before it could be absorbed into the bloodstream. For research purposes, it is administered via injection to ensure it reaches systemic circulation intact.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Calculate TB-500 Concentration — Reconstitution Guide

A 2023 analysis of peptide reconstitution protocols submitted to research institutions found that nearly 40% contained dosing calculation errors. Not contamination issues, not storage failures, but incorrect math that rendered the entire vial either underdosed or dangerously concentrated. The most common mistake: assuming the peptide amount on the vial label represents the concentration per injection rather than the total peptide mass in the vial. TB-500 (Thymosin Beta-4), supplied as lyophilised powder in 5mg or 10mg vials, requires precise reconstitution with bacteriostatic water to achieve the intended research dose. And the concentration you create depends entirely on how much solvent you add. We've worked with research teams across multiple institutions handling peptide reconstitution for biological studies. The gap between doing this correctly and wasting an entire vial comes down to understanding one formula and applying it before you touch the syringe. How do you calculate TB-500 concentration after reconstitution? To calculate TB-500 concentration, divide the total peptide mass in the vial (in milligrams) by the volume of bacteriostatic water added (in milliliters). A 5mg vial reconstituted with 2mL yields 2.5mg/mL. Meaning each 0.1mL (10 units on an insulin syringe) contains 0.25mg of TB-500. The concentration determines how much volume you draw to achieve your target dose. Most guides explain how to reconstitute TB-500. Add bacteriostatic water, swirl gently, refr…
DOSAGE SOURCE

The Unvarnished Truth About TB-500 Dosing Protocols

Here's the honest answer: most TB-500 protocols dose for convenience, not for pharmacokinetics. Once-weekly administration became standard because it's easy to remember and fits supplement-style dosing habits. Not because it matches the peptide's elimination curve. TB-500's terminal half-life of 24–48 hours means plasma concentrations drop below therapeutic levels within 72 hours, creating multi-day gaps where tissue repair signalling stops. The research demonstrating TB-500 efficacy used continuous infusion or daily dosing in animal models. Not weekly boluses. Translating those findings to once-weekly human protocols ignores the pharmacokinetic reality entirely. If a research team wants sustained tissue-level actin binding throughout a 14–21 day repair window, twice-weekly dosing (every 3–4 days) is the minimum frequency that maintains plasma levels above threshold. Weekly dosing produces four days of therapeutic effect followed by three days of subtherapeutic trough. And wondering why outcomes don't match published studies. Rigorous research protocols demand pharmacokinetic alignment. At Real Peptides, every batch undergoes HPLC verification to confirm >98% purity and accurate amino acid sequencing. Ensuring the peptide you reconstitute has the pharmacokinetic profile the literature describes, not a degraded variant with unpredictable absorption and clearance. Our Healing Total Recovery Bundle combines TB-500 with BPC-157 to address both actin-mediated repair (TB-500) and …
02

Question drills

Open a question for its connected answer.

01What If My Protocol Requires 4 mL Total Volume — Can I Split It Across Routes?+

Yes. Splitting a high-volume TB-500 dose across both SubQ and IM sites is acceptable and won't compromise systemic bioavailability. Example: administer 1.5 mL SubQ in the abdomen and 2.5 mL IM in the vastus lateralis. Both depots contribute to the same plasma concentration curve within 3–4 hours. The only consideration is injection site rotation: avoid using the same SubQ or IM location more than once per week to prevent localized inflammation or lipohypertrophy.

SOURCE / realpeptides.co ↗
02What If Your Flight Is Delayed on the Tarmac for Hours?+

Move your cooler to the coldest available location—under the seat in front of you rather than the overhead bin, and away from windows. Overhead bins experience radiant heat from the fuselage and can reach 30–35°C during tarmac delays in summer. If the delay exceeds 3 hours and you're carrying reconstituted peptides, accept that cold chain integrity is likely compromised and plan to discard the sample upon arrival. For lyophilised powder, the risk is lower—most formulations tolerate brief temperature excursions, but document the delay duration and storage conditions so you can disclose them during your research protocol. If carrying multiple vials, consider sacrificing one as a temperature control—if it shows discoloration, precipitate, or unusual appearance upon arrival, discard the entire batch.

SOURCE / realpeptides.co ↗
03What If I Combine TB-500 with BPC-157 or Other Peptides?+

BPC-157 acts through different pathways. It promotes VEGF receptor expression and modulates nitric oxide signaling, while TB-500 works via actin binding and direct VEGF upregulation. Theoretically, the mechanisms are complementary, but no controlled studies have tested combination protocols. Our team has found that researchers investigating multi-peptide approaches typically stagger administration (BPC-157 daily, TB-500 twice weekly) to avoid receptor saturation, though this is empirical rather than evidence-based.

SOURCE / realpeptides.co ↗
04What If TB-500 Reconstituted Cloudy But There's No Smell or Sediment?+

Absence of odor doesn't confirm safety. Protein aggregation produces no smell but completely destroys peptide efficacy. Cloudiness without sediment typically indicates pH-induced precipitation or early-stage aggregation rather than advanced bacterial growth. The solution is still unusable for research. Test your bacteriostatic water's pH with indicator strips. If it's outside the 5.5–7.0 range, that's your culprit.

SOURCE / realpeptides.co ↗
05What If a Research Protocol Requires Both Collagen Synthesis and Angiogenesis?+

Combine both peptides in a stacked protocol with staggered administration timing. AHK-Cu and TB-500 operate through non-overlapping pathways, making concurrent use mechanistically sound for models examining complex wound healing that involves both matrix deposition and vascular network formation. Administer AHK-Cu daily (or topically in dermal models) to maintain copper-dependent lysyl oxidase activity, and dose TB-500 twice weekly to sustain actin regulation and endothelial migration. This approach has been employed in published research examining full-thickness dermal wounds in rodent models, where collagen architecture and capillary density are both measured endpoints. Monitor for copper toxicity if AHK-Cu dosing exceeds physiological thresholds. Serum copper levels above 150 µg/dL can inhibit fibroblast proliferation rather than promote it.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Important Considerations for Laboratory Research

Embarking on research with any peptide requires impeccable attention to detail. This is where we, as a company, place our entire focus. The integrity of your results depends entirely on the quality of the compounds you use. We can't stress this enough. First and foremost is purity and sourcing. The peptide market is, frankly, flooded with low-quality products. Contaminants, incorrect sequences, or low purity levels can completely invalidate your research and lead to misleading results. This is why at Real Peptides, every batch of our TB-500 (thymosin Beta-4) undergoes rigorous third-party testing to guarantee its identity, purity, and concentration. When you're trying to determine what is TB 500's true effect, you can't have any confounding variables from a subpar product. It’s a non-starter. Next comes reconstitution and storage. Peptides like TB-500 are delivered as a lyophilized (freeze-dried) powder to ensure stability during shipping. To be used in research, they must be carefully reconstituted with a sterile solvent. Our team always recommends using high-quality Bacteriostatic Reconstitution Water (bac), which contains a small amount of benzyl alcohol to prevent bacterial growth. Once reconstituted, the peptide is no longer shelf-stable and must be refrigerated to maintain its integrity. Proper handling isn't just a best practice; it's a mandatory requirement for valid scientific inquiry. Finally, when it comes to protocols and administration in a research setting, it's vital to consult existing scientific literature. While we cannot provide dosing advice for obvious reasons, published studies on animal models typically describe a 'loading phase' followed by a 'maintenance phase.' The loading phase involves more frequent administration to quickly raise systemic levels of the peptide, while the maintenance phase uses less frequent administration to sustain those levels. Understanding these established research models is part of the due diligence required to properly investigate what is TB 500.

RESEARCH

What Is TB-500? Complete Research-Use-Only Guide

What Is TB-500? A Complete Research-Use-Only Guide TB-500 is a synthetic peptide related to an active region of thymosin beta-4, studied in laboratory and animal-model research. A complete research-use-only guide. Research-use-only context. This is a molecular-biology overview of TB-500 and its parent peptide thymosin beta-4 (Tβ4), based on published in vitro and pre-clinical literature. It is not a dosing guide, not an efficacy claim, not medical advice, and not a recommendation for human or animal use. American Peptides supplies TB-500 for in vitro research only. TB-500 is a synthetic peptide based on thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering protein (~4,963 Da) first identified in calf thymus and later shown to be the dominant G-actin-binding peptide in most mammalian cells (Safer, Elzinga & Nachmias, 1991). In the research literature, "TB-500" most commonly refers not to the full Tβ4 protein but to a short, N-terminally acetylated synthetic fragment corresponding to residues 17–23 of Tβ4 — the sequence Ac-LKKTETQ — which contains the actin-binding motif (Ho et al., 2012; Esposito et al., 2012). Some research-peptide suppliers also use the "TB-500" label for full-length synthetic Tβ4; always verify the sequence on the Certificate of Analysis. Below is the molecular-biology breakdown for working researchers — strictly receptor- and pathway-level pharmacology, no outcome claims. What TB-500 actually is at the molecular level The confusion around TB-500 starts at nomenclature, so it helps to separate three related entities: Thymosin beta-4 (Tβ4) 43 amino acids (full sequence beginning SDKPDMAEI…) ~4,963 Da The endogenous protein. Dominant intracellular G-actin-sequestering peptide. TB-500 (research-peptide label) Most commonly the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ (7 aa) ~889 Da (Ac-LKKTETQ-OH) A synthetic fragment encompassing Tβ4’s actin-binding motif. Characterized in doping-control literature (Esposito et al., 2012). AC-SDKP Ac-Ser-Asp-Lys-Pro (residues 1–4 of Tβ4) ~487 Da A separate N-terminal tetrapeptide cleaved from Tβ4 in vivo by prolyl oligopeptidase. Studied independently as an angiogenic / anti-fibrotic factor (Wang et al., 2004). Conflating these three molecules is one of the most common errors in the secondary literature. Tβ4 is the full protein, TB-500 is most often a short actin-binding fragment of it, and AC-SDKP is a different short fragment with its own pharmacology. All three are studied in different assay systems with different readouts. The actin-sequestering mechanism Tβ4’s defining biochemical activity was established by Safer, Elzinga and Nachmias in 1991, who showed that the previously characterized actin-sequestering peptide "Fx" was sequence-identical to Tβ4 and forms a 1:1 complex with G-actin monomers, inhibiting their polymerization into F-actin filaments (Safer, Elzinga & Nachmias, 1991). Later mutational mapping localized the critical actin-binding contacts to the central helical region of Tβ4, with the 17-LKKTETQ-23 motif identified as essential for the actin interaction (Van Troys et al., 1996). Biophysical studies confirmed that Tβ4 binding measurably changes the conformation and dynamics of the actin monomer itself (De La Cruz et al., 2000). This is the molecular rationale for the "TB-500" design: synthesizing the 17–23 actin-binding motif as a stand-alone short peptide allows researchers to study an actin-interaction signal independent of the rest of the Tβ4 sequence, in a molecule that is far simpler to synthesize, characterize, and quantify by mass spectrometry. Tβ10 was subsequently shown to share the same monomer-sequestering function, establishing β-thymosins as a family of actin regulators (Yu et al., 1993). Wound-healing and migration pathways studied in animal models Beyond pure actin biochemistry, Tβ4 has been studied in a range of injury and migration models. In the Goldstein-lab program at George Washington University, Tβ4 was reported to accelerate corneal re-epithelialization and reduce inflammatory infiltrate after alkali injury in mice, with several inflammatory chemokines reduced several-fold in treated corneas versus controls (Sosne et al., 2002). That program later progressed to clinical research on Tβ4 eyedrops for dry eye and neurotrophic keratopathy (Sosne, 2018). In a separate landmark paper, Bock-Marquette and colleagues reported in Nature that Tβ4 forms a complex with PINCH and integrin-linked kinase (ILK), activating Akt and promoting cardiomyocyte and endothelial-cell migration and survival in a mouse coronary-ligation model (Bock-Marquette et al., 2004). The broader regenerative biology of Tβ4 across dermatology, ophthalmology, and cardiology was synthesized in a 2012 review from the Goldstein, Hannappel, Sosne and Kleinman labs (Goldstein et al., 2012). AC-SDKP: the separate N-terminal tetrapeptide Tβ4 is also a substrate for prolyl oligopeptidase, which liberates the N-terminal tetrapeptide AC-SDKP (Ac-Ser-Asp-Lys-Pro). AC-SDKP is then degraded by angiotensin-converting enzyme (ACE) — the same enzyme targeted by cardiovascular ACE inhibitors — which is one reason it has received independent attention. In published animal and in vitro studies, AC-SDKP stimulates endothelial-cell proliferation, migration, and tube formation in a dose-dependent manner and increases capillary density after myocardial infarction in rodent models (Wang et al., 2004). It is mechanistically distinct from the LKKTETQ-style "TB-500" fragment: AC-SDKP signals via angiogenic / anti-fibrotic pathways rather than through direct G-actin binding. Comparative peptides table TB-500 (Ac-LKKTETQ) 17–23 actin-binding fragment of Tβ4 Actin sequestration, cell-migration assays Full Tβ4 (43 aa) Native peptide Wound healing, corneal repair, cardiac repair (Goldstein et al., 2012) Residues 1–4 of Tβ4, cleaved by prolyl oligopeptidase Angiogenesis, anti-fibrosis (Wang et al., 2004) BPC-157 Unrelated; gastric-juice-derived peptide Often studied alongside TB-500 in pre-clinical tissue-repair literature Why purity and sequence verification matter Because "TB-500" is a label rather than a single defined sequence in commerce, batch-specific verification is non-negotiable for a working researcher. The minimum questions a Certificate of Analysis (COA) should answer: What is the actual sequence in this vial? Ac-LKKTETQ-OH (the 7-aa fragment), full 43-aa Tβ4, or something else entirely? Mass-spectrometry data should match the claimed sequence within typical instrument tolerance. What is the HPLC purity? Common synthesis impurities at this length include deletion sequences and incomplete acetylation; both shift the apparent pharmacology in actin-binding assays. Does the lot number on the vial match the lot number on the COA? Lot mismatch is a frequent source of irreproducibility in peptide research. Every TB-500 lot we ship has independent third-party HPLC and mass-spectrometry verification at ≥99% purity. See current COAs. Laboratory handling TB-500 is supplied lyophilized for stability. Reconstitution, storage temperature, light exposure, and freeze-thaw cycle count all measurably affect short-peptide integrity in published stability work. Researchers should keep reconstituted stocks cold and protected from light, minimize freeze-thaw cycles, and maintain lot traceability against the COA. This is bench-chemistry guidance for in vitro research only — it is not administration guidance, and TB-500 is not a drug, supplement, food, or medical product. Frequently Asked Questions What is the difference between TB-500 and full thymosin beta-4? Thymosin beta-4 (Tβ4) is the full 43-amino-acid endogenous protein (~4,963 Da), first identified as the dominant G-actin-sequestering peptide in mammalian cells (Safer, Elzinga & Nachmias, 1991). "TB-500" is a research-peptide label most commonly applied to a short, N-terminally acetylated synthetic fragment, Ac-LKKTETQ, corresponding to residues 17–23 of Tβ4 — the region carrying the actin-binding motif characterized by mutational mapping (Van Troys et al., 1996; Esposito et al., 2012). Some suppliers use the "TB-500" label for full-length synthetic Tβ4; verify against the lot COA. How does TB-500 relate to actin? The 17–23 LKKTETQ region of Tβ4 makes the critical contacts with G-actin monomers; deletions or mutations in this region abolish the actin interaction in published mutational studies (Van Troys et al., 1996). The parent Tβ4 protein forms a 1:1 complex with G-actin and prevents its polymerization into F-actin filaments (Safer, Elzinga & Nachmias, 1991), and Tβ4 binding measurably alters monomer conformation and dynamics (De La Cruz et al., 2000). The TB-500 fragment is studied as an isolated probe of this actin-binding motif. Why is TB-500 studied alongside BPC-157? The two peptides are sequence- and origin-unrelated — TB-500 is a Tβ4 fragment, BPC-157 is a synthetic peptide derived from a gastric-juice protein — but they are frequently paired in pre-clinical tissue-repair literature because they engage different mechanisms of interest in injury models. TB-500’s research context centers on actin-sequestering and cell-migration pathways (Safer, Elzinga & Nachmias, 1991); BPC-157’s pre-clinical literature emphasizes nitric-oxide and growth-factor signaling. Researchers designing comparator studies should be explicit that these are distinct pathways studied in distinct assay systems — not interchangeable molecules. What is AC-SDKP and is it the same as TB-500? No. AC-SDKP (Ac-Ser-Asp-Lys-Pro) is the N-terminal tetrapeptide cleaved from Tβ4 by prolyl oligopeptidase — residues 1–4 of the parent protein — and is studied for angiogenic and anti-fibrotic activity in endothelial and cardiac models (Wang et al., 2004). TB-500, as most commonly characterized in the analytical-chemistry literature, is the 17–23 actin-binding fragment Ac-LKKTETQ (Esposito et al., 2012). Different residues, different mechanism, different pharmacology. Is TB-500 approved for human or veterinary use? No. TB-500 is not approved as a drug, supplement, food, or medical product in any jurisdiction we are aware of, and it is prohibited in equine sport — the analytical-chemistry literature on TB-500 detection was developed largely for veterinary doping control (Ho et al., 2012). American Peptides supplies TB-500 strictly for in vitro laboratory research. What molecular weight should I expect on the COA? If the lot is the standard Ac-LKKTETQ-OH fragment, the monoisotopic / average mass should be near ~889 Da. If the lot is full-length synthetic Tβ4 (43 aa), the mass should be near ~4,963 Da. If your COA does not match either, the material is not what is conventionally labeled TB-500 — do not proceed without sequence clarification from the supplier. How should TB-500 be handled in the lab? Store lyophilized at −20 °C or colder. Reconstitute in an appropriate aqueous buffer immediately before use, keep reconstituted stocks cold and protected from light, aliquot to minimize freeze-thaw cycles, and maintain lot-number traceability against the COA. This is bench-chemistry handling guidance only — not administration guidance. Citations Safer D., Elzinga M., Nachmias V.T. "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable." J Biol Chem. 1991;266(7):4029–4032. PubMed. Yu F.X., Lin S.C., Morrison-Bogorad M., Atkinson M.A., Yin H.L. "Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins." J Biol Chem. 1993;268(1):502–509. PubMed. Van Troys M., Dewitte D., Goethals M., Carlier M.F., Vandekerckhove J., Ampe C. "The actin binding site of thymosin beta 4 mapped by mutational analysis." EMBO J. 1996;15(2):201–210. PubMed. De La Cruz E.M., Ostap E.M., Brundage R.A., Reddy K.S., Sweeney H.L., Safer D. "Thymosin-beta(4) changes the conformation and dynamics of actin monomers." Biophys J. 2000;78(5):2516–2527. PubMed. Sosne G., Szliter E.A., Barrett R., Kernacki K.A., Kleinman H., Hazlett L.D. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293–299. PubMed. Wang D., Carretero O.A., Yang X.Y., Rhaleb N.E., Liu Y.H., Liao T.D., Yang X.P. "N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo." Am J Physiol Heart Circ Physiol. 2004;287(5):H2099–H2105. PubMed. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466–472. PubMed. Goldstein A.L., Hannappel E., Sosne G., Kleinman H.K. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37–51. PubMed. Esposito S., Deventer K., Goeman J., Van der Eycken J., Van Eenoo P. "Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential." Drug Test Anal. 2012;4(9):733–738. PubMed. Ho E.N., Kwok W.H., Lau M.Y., Wong A.S., Wan T.S., Lam K.K., Schiff P.J., Stewart B.D. "Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry." J Chromatogr A. 2012;1265:57–69. PubMed. Sosne G. "Thymosin beta 4 and the eye: the journey from bench to bedside." Expert Opin Biol Ther. 2018;18(sup1):99–104. PubMed. This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human or animal consumption, not a drug, not a supplement, not a medical product. Last reviewed: 2026-05-25 by American Peptides Research Team.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles